MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, will be listed on Nasdaq under the ticker "MLTX"

On April 5, MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced the closing of its previously announced business combination with Helix Acquisition Corp. ("Helix"), a publicly traded special purpose acquisition company. The business combination was unanimously approved by Helix's board of directors and was approved by Helix's shareholders at an extraordinary general meeting on March 31, 2022. In connection with the closing, Helix changed its name to MoonLake Immunotherapeutics ("MoonLake" or the "Company"). Beginning today, MoonLake's shares will trade on the Nasdaq Stock Market under the ticker symbol "MLTX." MoonLake plans to execute on its development program to unlock the potential of sonelokimab (M1095), a novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.

Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics AG on this transaction. The team of Kellerhals Carrard comprised Nicolas Mosimann (Lead), Emmanuel Dettwiler, Kevin MacCabe, Marco Sibold, Jon Oetiker, Dario Ammann (all Corporate/M&A), Oliver Brupbacher (Regulatory), Claudia Staehelin (Compliance) and Christine Bassanello (Employment Law).